Jefferies Maintains Buy on Dianthus Therapeutics, Raises Price Target to $81
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Maury Raycroft maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $66 to $81.
Jefferies analyst Maury Raycroft maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $66 to $81.